Drug Trial Radar · NCT06640920
A Study to Investigate Efficacy and Safety of NSI-8226 in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Apr 29, 2024
Primary completion
Oct 29, 2024
Study completion Oct 29, 2024
Sponsor
- Lead sponsor
- Uniquity One (UNI)Industry
- Sponsor type
- Industry
- First posted
- Oct 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 1 Randomized, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Bioavailability of NSI-8226 in Healthy Participants.
Conditions
- Healthy
Interventions
Cohort ABiological
Administered IV High dose
Cohort BBiological
Administered SC Low Dose
Cohort CBiological
Administered SC Mid Dose
Cohort DBiological
Administered SC High Dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerabilityTime frame: 140 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Cincinnati, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.